Systemic Mastocytosis Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 8+ Companies and 8+ Therapies
DelveInsight's, 'Systemic Mastocytosis Pipeline Insight, 2025,' report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Systemic Mastocytosis pipeline landscape. It covers the Systemic Mastocytosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Systemic Mastocytosis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment options in the Systemic Mastocytosis Pipeline. Dive into DelveInsight's comprehensive report today! @ Systemic Mastocytosis Pipeline Outlook
Key Takeaways from the Systemic Mastocytosis Pipeline Report
In May 2025, M.D. Anderson Cancer Center announced a clinical research study is to see if RAD001 can help to control the disease in patients with systemic mastocytosis (SM). The safety of this treatment will also be studied. RAD001 is designed to stop cancer cells from multiplying. It may also stop the growth of new blood vessels that help tumor growth, which may cause the tumor cells to die.
In May 2025, Cogent Biosciences Inc. announced a Phase 2 study investigating CGT9486 for the treatment of patients with Advanced Systemic Mastocytosis (AdvSM), including patients with Aggressive SM (ASM), SM with Associated Hematologic Neoplasm (SM-AHN), and Mast Cell Leukemia (MCL).
DelveInsight's Systemic Mastocytosis Pipeline report depicts a robust space with 8+ active players working to develop 8+ pipeline therapies for Systemic Mastocytosis treatment.
The leading Systemic Mastocytosis Companies such as AB Sciences, Blueprint Medicines, Patara Pharma, Seagen Inc., GT Biopharma, Deciphera Pharmaceuticals, Novartis Oncology and others.
Promising Systemic Mastocytosis Pipeline Therapies such as PA101, Avapritinib, RAD001 (Everolimus), Elenestinib, Masitinib, Avapritinib, Brentuximab vedotin, TL-895 and others.
Stay ahead with the most recent pipeline outlook for Systemic Mastocytosis. Get insights into clinical trials, emerging therapies, and leading companies with Systemic Mastocytosis @ Systemic Mastocytosis Treatment Drugs
Systemic Mastocytosis Emerging Drugs Profile
Avapritinib: Blueprint Medicines
Avapritinib is a potent and selective inhibitor of activated KIT and PDGFRA mutant kinases. In certain diseases, mutations in KIT and PDGFRA force protein kinases into an increasingly active state. Avapritinib is uniquely designed to bind and inhibit the active conformation of these proteins. Blueprint Medicines is developing AYVAKIT globally for the treatment of advanced and indolent SM. Blueprint Medicines has an exclusive collaboration and license agreement with CStone Pharmaceuticals for the development and commercialization of AYVAKIT in Mainland China, Hong Kong, Macau and Taiwan. Blueprint Medicines retains development and commercial rights for AYVAKIT in the rest of the world. The FDA granted breakthrough therapy designation to AYVAKIT for the treatment of advanced SM, including the subtypes of aggressive SM, SM with an associated hematological neoplasm and mast cell leukemia, and for the treatment of moderate to severe indolent SM. The FDA has accepted a supplemental new drug application for avapritinib for the treatment of advanced SM. The European Medicines Agency has validated a Type II variation marketing authorization application for avapritinib for the treatment of advanced SM.
Masitinib: AB Sciences
Masitinib's anti-mast cell properties appear particularly well-adapted to the treatment of indolent systemic mastocytosis. A reduction of mast cell activity is generated via its inhibitory action on wild-type c-Kit, Lyn and Fyn tyrosine kinases. In recognition of the critical need for new treatments, masitinib received orphan drug designation for mastocytosis from both the European Medicine Agency (EMA) and the U.S. Food and Drug Administration (FDA). AB Science initiated a confirmatory phase 3 study, with design optimized based on findings from the first phase 3 study.
The Systemic Mastocytosis Pipeline Report Provides Insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Systemic Mastocytosis with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Systemic Mastocytosis Treatment.
Systemic Mastocytosis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Systemic Mastocytosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Systemic Mastocytosis market
Explore groundbreaking therapies and clinical trials in the Systemic Mastocytosis Pipeline. Access DelveInsight's detailed report now! @ New Systemic Mastocytosis Drugs
Systemic Mastocytosis Companies
AB Sciences, Blueprint Medicines, Patara Pharma, Seagen Inc., GT Biopharma, Deciphera Pharmaceuticals, Novartis Oncology and others.
Systemic Mastocytosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Oral
Parenteral
Intravenous
Subcutaneous
Topical
Molecule Type
Systemic Mastocytosis Products have been categorized under various Molecule types such as
Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy
Product Type
Unveil the future of Systemic Mastocytosis Treatment. Learn about new drugs, Systemic Mastocytosis Pipeline developments, and key companies with DelveInsight's expert analysis @ Systemic Mastocytosis Market Drivers and Barriers
Scope of the Systemic Mastocytosis Pipeline Report
Coverage- Global
Systemic Mastocytosis Companies- AB Sciences, Blueprint Medicines, Patara Pharma, Seagen Inc., GT Biopharma, Deciphera Pharmaceuticals, Novartis Oncology and others.
Systemic Mastocytosis Pipeline Therapies- PA101, Avapritinib, RAD001 (Everolimus), Elenestinib, Masitinib, Avapritinib, Brentuximab vedotin, TL-895 and others.
Systemic Mastocytosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Systemic Mastocytosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Systemic Mastocytosis Pipeline Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Systemic Mastocytosis Companies, Key Products and Unmet Needs
Table of Content
Introduction
Executive Summary
Systemic Mastocytosis: Overview
Pipeline Therapeutics
Therapeutic Assessment
Systemic Mastocytosis – DelveInsight's Analytical Perspective
In-depth Commercial Assessment
Systemic Mastocytosis Collaboration Deals
Late Stage Products (Preregistration)
Avapritinib: Blueprint Medicines
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
PA101: Patara Pharma
Drug profiles in the detailed report…..
Early stage products (Phase I)
DCC-2618: Deciphera Pharmaceuticals
Drug profiles in the detailed report…..
Inactive Products
Systemic Mastocytosis Key Companies
Systemic Mastocytosis Key Products
Systemic Mastocytosis- Unmet Needs
Systemic Mastocytosis- Market Drivers and Barriers
Systemic Mastocytosis- Future Perspectives and Conclusion
Systemic Mastocytosis Analyst Views
Systemic Mastocytosis Key Companies
Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/systemic-mastocytosis-pipeline-insight
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
National Post
33 minutes ago
- National Post
Amazfit Expands Active 2 Lineup with the New Active 2 Square -- All the Same Features, Now in a Sleek Square Design
Article content MILPITAS, Calif. — Amazfit, a leading global smart wearable brand owned by Zepp Health (NYSE: ZEPP), a health technology company, today announced the launch of the square version of the Amazfit Active 2, a new addition to its fitness smartwatch line that offers the same powerful features and premium experience as the recently launched round Active 2 — now in a modern, square form factor. Article content Featuring a square, 1.75 inch sapphire glass high-definition AMOLED display elegantly encased in a polished stainless-steel frame. Article content Article content Same Features. New Shape. Article content Debuting at CES 2025 and featured at Pepcom and ShowStoppers, the Active 2 Square is designed for consumers who prefer a bold, geometric aesthetic without compromising performance, durability, or advanced health and fitness tracking. Article content Featuring a square, 1.75 inch sapphire glass high-definition AMOLED display elegantly encased in a polished stainless-steel frame, the Amazfit Active 2 delivers an optimal visual experience with a peak brightness of 2,000 nits, ensuring clarity even in bright light. Article content The graceful metal finish adds a sophisticated touch, perfectly complementing modern, style-conscious lifestyles. Its distinctive geometric form reflects a unique design identity and its intuitive interface and expansive viewing surface provide seamless access to health metrics, messages, and workouts. The device retains the full suite of features that made the round Active 2 a standout. Article content Product Specs Article content Latest Generation Biosensor: The BioTracker™ 6.0 PPG biosensor features a dual-LED and 5PD build, which picks up more biometric signals for enhanced precision in health monitoring and measurement. Upgraded Heart Rate and Sleep Algorithms: The PulsePrecision™ algorithm enhances heart rate tracking accuracy to the level of the Amazfit T-Rex 3, while the RestoreIQ™ algorithm gives sleep monitoring a similar accuracy boost. Additional Sensors: Compared to the previous generation of Amazfit Active, the new release adds a barometer for accurate altitude measurements and support of new sports like skiing, along with an accelerometer and gyroscope for precise recognition of sleep and movement, and an ambient light sensor for optimal display under varying light conditions. Extended Battery Life: With a robust 10-day battery life under typical use, the Active 2 Square is a device that won't need recharging every night. Zepp Flow™: Enables users to control their watch settings, adjust their calendar, and more with just their voice, while also granting Android users the ability to reply to instant messages with either keyboard or speech-to-text input. Article content Fitness and Wellness Features Article content Dynamic Fitness Modes: Over 160 sports modes including official HYROX Race Mode, a smart Strength Training mode that can auto-detect specific exercises and intelligently count reps, sets, and rest time, and new winter sports like Skiing. Offline Maps with Turn Directions: Supported by 5 satellite systems, users can navigate with ease by importing offline maps and route files to the watch that come with turn-by-turn directions, which can be followed on-screen or broadcast via the built-in speaker or the user's connected Bluetooth headphones. Zepp Coach™ Integration: Offers personalized training and running plans, empowering users of all levels to achieve fitness milestones from 3K runs to full marathons. Tailored for Women: With the mini app, women can connect to their accounts directly from the watch for personalized wellness insights tied to their menstrual and hormonal cycles. Advanced Health Insights: A daily Readiness score summarizes mental and physical recovery and provides actionable insights, while the HRV feature delivers specialized recovery data. Article content Availability and Pricing Article content The Amazfit Active 2 Square is available for purchase beginning today on and Amazon. Priced at $149.99 USD or €149.90 euro, the Active 2 Square delivers premium features and performance at an unbeatable value. Article content About Amazfit Article content Amazfit, a leading global smart wearable brand focused on health and fitness, is part of Zepp Health (NYSE: ZEPP), a health technology company with its principal office based in Gorinchem, the Netherlands. Zepp Health operates as a distributed organization, with team members and offices across the Americas, Europe, Asia, and other global markets. Article content Offering a wide selection of smartwatches and bands, Amazfit's brand tagline, 'Discover Amazing,' encourages individuals to break barriers, exceed expectations, and find joy in every moment. Amazfit is powered by Zepp Health's proprietary health management platform, which delivers cloud-based, 24/7 actionable insights and guidance to help users achieve their wellness goals. Article content Known for outstanding craftsmanship, Amazfit smartwatches have won numerous design awards, including the iF Design Award and the Red Dot Design Award. Launched in 2015, Amazfit is embraced by millions of users, with products available in over 90 countries across the Americas, EMEA, and APAC regions. For more information, visit Article content Article content Article content Article content Article content Contacts Article content Media Contact Article content Article content Article content
CTV News
an hour ago
- CTV News
CTV National News: How realistic is a 30-day deadline for a trade deal with Canada?
Watch Vassy Kapelos explains why U.S. and Canadian officials believe a 30-day timeline for a bilateral trade deal is realistic.
Globe and Mail
an hour ago
- Globe and Mail
Cal Redwood Acquisition Corp. Announces the Separate Trading of Its Class A Ordinary Shares and Rights, Commencing on June 23, 2025
Menlo Park, CA, June 16, 2025 (GLOBE NEWSWIRE) -- Cal Redwood Acquisition Corp. (Nasdaq: CRAQU) (the ' Company ') today announced that, commencing on June 23, 2025, holders of the units (the ' Units ') sold in the Company's initial public offering may elect to separately trade the Company's Class A ordinary shares (the ' Ordinary Shares ') and rights (the ' Rights ') included in the Units. The Ordinary Shares and Rights received from the separated Units will trade on the Nasdaq Global Market (' Nasdaq ') under the symbols 'CRA' and 'CRAQR', respectively. Units that are not separated will continue to trade on Nasdaq under the symbol 'CRAQU'. Holders of Units will need to have their brokers contact Lucky Lucko, Inc. d/b/a Efficiency, the Company's transfer agent, in order to separate the Units into Ordinary Shares and Rights. The Company was formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The Company may pursue an initial business combination opportunity in any industry or sector but expects to focus its efforts on businesses in the technology, media and telecommunications (TMT) sector as well as sectors that are being transformed via technology disruption, where the Company believes its management team's operational and investment expertise will provide it with a competitive advantage. The Units were initially offered by the Company in an underwritten offering. Cohen & Company Capital Markets, a division of J.V.B. Financial Group, LLC, acted as lead book-running manager, and Seaport Global Securities acted as joint book runner. Copies of the prospectus relating to the offering may be obtained from Cohen & Company Capital Markets, 3 Columbus Circle, 24th Floor, New York, NY 10019, Attention: Prospectus Department, or by email at: capitalmarkets@ The registration statement relating to the securities of the Company was declared effective by the U.S. Securities and Exchange Commission (the ' SEC ') on May 22, 2025. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Forward Looking Statements This press release contains statements that constitute 'forward-looking statements' that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company's registration statement and final prospectus for the Company's initial public offering filed with the SEC, which could cause actual results to differ from forward-looking statements. Copies of these documents are available on the SEC's website, at The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law. No assurance can be given that the Company will ultimately complete a business combination transaction. Contact
